Further mechanistical analyses revealed, that Ruxolitinib ameliorates GVHD by disrupting Th1 and Th17 differentiation but promoting Treg differentiation via indirect STAT1 and STAT3 inhibition (223). Here, STAT3 is linked to graft versus host disease.